Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia

Tadeusz Robak, Andrzej Hellmann, Janusz Kloczko, Javier Loscertales, Ewa Lech-Maranda, John M. Pagel, Anthony Mato, John C. Byrd, Farrukh T. Awan, Holger Hebart, Jose A. Garcia-Marco, Brian T. Hill, Michael Hallek, Amy J. Eisenfeld, Scott C. Stromatt, Ulrich Jaeger

Research output: Contribution to journalArticlepeer-review

28 Scopus citations

Fingerprint

Dive into the research topics of 'Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia'. Together they form a unique fingerprint.

Medicine & Life Sciences